{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:01Z","timestamp":1787721661701,"version":"build-2784847793"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    CAR T cell therapies have shown clinical success in several tumor types, though not in breast cancer, for which advanced stages remain incurable. CD70 is expressed in a broad range of solid tumor types and is emerging as a molecular target for CAR T cells in renal and ovarian malignancies. Here we show that a subset of breast cancer cell lines and patient-derived xenografts express CD70, albeit to varying levels. Leveraging a recently developed HLA-independent T cell (HIT) receptor with greater sensitivity to CD70 than conventional CAR designs, we assessed whether CD70 can be targeted to eliminate breast cancer cells. We observed that CD70-targeted HIT T cells showed antigen-specific activation\n                    <jats:italic>in vitro<\/jats:italic>\n                    , and cytotoxicity against breast cancer cell lines and patient-derived xenograft cells across a broad range of CD70 levels. Implanted in the murine mammary fat pad, high CD70-expressing patient-derived xenografts were readily eliminated by both conventional CAR and HIT T cells. Against xenografts with lower CD70 expression, however, CD70-targeted HIT T cells engineered with supplemental costimulation outperformed conventional CAR T cells by inhibiting tumor outgrowth in mice, and conferred a significant survival benefit. These findings establish that CD70 is a targetable antigen in breast cancer and highlight the potential of enhanced-sensitivity receptor designs such as HIT receptors to engage a broader range of tumors.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1852493","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:52:08Z","timestamp":1787719928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Control of breast cancer patient-derived xenografts by CD70-targeted HIT-CAR T cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Pieter L.","family":"Lindenbergh","sequence":"first","affiliation":[{"name":"Columbia Institute for Cell Engineering and Therapy (CICET), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center","place":["New York, NY, United States"]},{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinagolu K.","family":"Rajasekhar","sequence":"additional","affiliation":[{"name":"Orthopedic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Linkov","sequence":"additional","affiliation":[{"name":"Pathology Core Facility, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Mansilla-Soto","sequence":"additional","affiliation":[{"name":"Departments of Immunology, Bioengineering, and Blood & Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie A.","family":"Hanina","sequence":"additional","affiliation":[{"name":"Columbia Institute for Cell Engineering and Therapy (CICET), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Columbia Institute for Cell Engineering and Therapy (CICET), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18060911","article-title":"Immunotherapies for breast cancer: From checkpoint inhibition to emerging cellular therapies","volume":"18","author":"Tsagkaraki","year":"2026","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3083","article-title":"Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells","volume":"14","author":"Sprowl","year":"2012","journal-title":"Breast Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1438107","article-title":"Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells","volume":"7","author":"Gravett","year":"2018","journal-title":"OncoImmunology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.151.11.6577","article-title":"Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors","volume":"151","author":"Stancovski","year":"1993","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900447","article-title":"A Herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity","volume":"183","author":"Zhao","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00493","article-title":"Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells","volume":"18","author":"Davies","year":"2012","journal-title":"Mol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade2526","article-title":"Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma","volume":"9","author":"Uslu","year":"2023","journal-title":"Sci Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011533","article-title":"B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer","volume":"13","author":"Stucchi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898","article-title":"Advancing CAR T-cell therapy in solid tumors: Current landscape and future directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887471","article-title":"The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/jca.10360","article-title":"CD70: a potential target in breast cancer","volume":"5","author":"Petrau","year":"2014","journal-title":"J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1126\/science.adv7378","article-title":"Sensitive CAR T cells redefine targetable CD70 expression in solid tumors","volume":"391","author":"Hanina","year":"2026","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.15.6733","article-title":"Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells","volume":"92","author":"Rivi\u00e8re","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41523-021-00266-0","article-title":"Anti-tumor effects of an ID antagonist with no observed acquired resistance","volume":"7","author":"Wojnarowicz","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor Pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf423","article-title":"GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research","volume":"53","author":"Kang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature24277","article-title":"Genetic effects on gene expression across human tissues","volume":"550","author":"Aguet","year":"2017","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.4.1756","article-title":"The cloning of CD70 and its identification as the ligand for CD27","volume":"152","author":"Bowman","year":"1994","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2005.04.004","article-title":"CD27 and CD70 in T cell and B cell activation","volume":"17","author":"Borst","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","article-title":"CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition","volume":"15","author":"Andreu-Saumell","year":"2024","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm1676","article-title":"T cell\u2013encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aea6276","article-title":"CAR T cell-derived TNF is an early determinant of cytokine release syndrome severity","volume":"11","author":"Lindenbergh","year":"2026","journal-title":"Sci Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/path.5361","article-title":"CD70 expression correlates with a worse prognosis in Malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness","volume":"250","author":"Inaguma","year":"2020","journal-title":"J Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.038","article-title":"Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer","volume":"169","author":"Ortiz-Cuaran","year":"2022","journal-title":"Eur J Cancer"},{"key":"B46","article-title":"Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma","volume":"62","author":"Wischhusen","year":"2002","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1593\/neo.06451","article-title":"Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes","volume":"8","author":"Diegmann","year":"2006","journal-title":"Neoplasia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1023064","article-title":"Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector Tregs","volume":"14","author":"Bowakim-Anta","year":"2023","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30830","article-title":"Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM","volume":"141","author":"Ge","year":"2017","journal-title":"Int J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00236-9","article-title":"Constitutive CD27\/CD70 interaction induces expansion of effector-type T cells and results in IFN\u03b3-mediated B cell depletion","volume":"15","author":"Arens","year":"2001","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2024.01.011","article-title":"Signaling via a CD27-TRAF2-SHP-1 axis during na\u00efve T cell activation promotes memory-associated gene regulatory networks","volume":"57","author":"Jaeger-Ruckstuhl","year":"2024","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.32","article-title":"Targeting the T-cell co-stimulatory CD27\/CD70 pathway in cancer immunotherapy: Rationale and potential","volume":"7","author":"van de Ven","year":"2015","journal-title":"Immunotherapy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive Malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells","volume":"11","author":"Han","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10059-010-0052-9","article-title":"Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer","volume":"29","author":"Yu","year":"2010","journal-title":"Mol Cells"},{"key":"B56","article-title":"Administering peripheral blood lymphocytes transduced with a CD70-binding chimeric antigen receptor to patients with CD70-expressing cancers","volume-title":"Clinicaltrials.Gov","author":"Yang","year":"2026"},{"key":"B57","article-title":"Clinical study of CD70-targeting CAR-T therapy in the treatment of CD70-positive advanced metastatic solid tumors","volume-title":"Clinicaltrials.Gov","author":"Fang","year":"2025"},{"key":"B58","article-title":"CD70 targeted CAR-T cells in CD70 positive advanced\/metastatic solid tumors","volume-title":"Clinicaltrials.Gov","author":"Han","year":"2023"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:52:19Z","timestamp":1787719939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2026.1852493"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1852493","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1852493"}}